Can the Vascular Physician Sensitize Patients to Redaction of Advance Directives on End of Life?
NCT ID: NCT02892175
Last Updated: 2016-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2015-05-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Moreover, according Régis Aubry, a researcher at the observatory on the end of life, the conditions of the end of life are insufficiently discussed with patients and their families and can lead to difficult situations conflicting view. Now, thinking about advance directives should allow an exchange on the conditions of the end of life desired by patients.
Sicard report of December 2012 concluded that such legislation is known neither patients nor doctors. This is the first obstacle to its use, even if major psychological barriers exist both in patients that their doctors.
It is in this context that Valls government asked MM. Claeys and Leonetti to propose a new bill on the subject. The bill provides that advance directives will no longer be valid for 3 years, but until changed or until the patient's death, and they can be invoked against doctors except emergency or illegality. In addition, to complete the bill, the Ministry of Health commissioned the National Health Authority (HAS) writing a form of advance directives, as well as a doctor's information guide and patient on the subject. The working group is chaired by Professor Sicard. Among the recommendations made to physicians (and by extension health professionals), the investigators accept that talk of advance directives as often as possible and as early as possible, even in the absence of commitment in the short or medium term prognosis .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation About Advance Directives
NCT03302052
The Opinion of Patients With Cancer on the Claeys-Leonetti Law, on Euthanasia and Determining Factors
NCT03664856
Home-based Nurse Intervention in the Care of High Risk of Death Patients After Discharge From Geriatric Department
NCT06481917
Assessment of Factors Involved in the Decision-making for ICU Patients' Care
NCT03013530
Better Understand End-of-life Emergencies' Management Among Elderly in Nursing Homes: a Pilot Study in Brittany, France
NCT02852733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Feasibility of addressing the topic of advance directives (% of patients agreeing to answer the questionnaire) during vascular medicine clinic in town.
Assessing preferences for editorial context to enable to present the project in optimal circumstances.
Assess felt an evolution of the doctor-patient relationship by patients in the context of advance directives.
Assess the reactions according to the characteristics of the study population to help develop different "profiles" and adapt the introduction of the topic of advance directives.
Methodology :
Design: prospective, single-center, non-interventional kind opinion survey Study duration: 6 months
Acquisition of data:
The characteristics of the population obtained will be studied to try to understand the feelings of patients, to better target patients to talk to about advance directives in vascular medicine and evaluate some extent if the topic of advance directives contributes to "modernize "the doctor-patient relationship.
* List of data gathered: cf. attached questionnaire
* Statistical analysis: local management (GHPSJ) from the patient profile
* Anonymity of data: an identifier for each subject will be awarded (first name and surname - year of birth) and the data will be entered on a computer file which will be sent to the statistician in charge of analyzing the GHPSJ site. There will be no personally identifiable data exchange.
Development of the study:
* Describe how the study: after information transmitted orally by the doctor (Dr P.Priollet) and patient's consent to participate, patients will be interviewed (attached schedule) and data gathered during consultations of office visits to Dr. Priollet city by Dr. Priollet assisted by Hélène Samson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
* Expected duration of patient recruitment: 3 months
* Number of patients to recruit 100 patients, 15 minutes per patient. At all times patients can freely return to the subject in subsequent consultations with Dr. Priollet.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Advance Directives on End of Life
after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Hôpital Saint-Joseph
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Paris Saint Joseph
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIRFIN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.